Skip to main content
Erschienen in: Surgical Endoscopy 7/2011

01.07.2011

Endoscopic resection of bladder cancer in patients receiving double platelet antiaggregant therapy

verfasst von: Luca Carmignani, Stefano Picozzi, Robert Stubinski, Stefano Casellato, Giorgio Bozzini, Luca Lunelli, Domenico Arena

Erschienen in: Surgical Endoscopy | Ausgabe 7/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

Approximately 5% of patients who have undergone coronary artery stenting require noncardiac surgery within a year of their cardiac intervention. European cardiological guidelines and recommendations from the U.S. Food and Drug Administration on platelet antiaggregant therapy following coronary artery stenting are for dual treatment with acetylsalicylic acid and clopidogrel, which should be continued for at least 12 months. The aim of this study was to evaluate the clinical course in patients receiving double platelet antiaggregant therapy who underwent transurethral resection of bladder cancer.

Methods

Between September 2007 and April 2010, twelve patients receiving double antithrombotic therapy (clopidogrel + acetylsalicylic acid) underwent transurethral resection of bladder cancer. In two cases the operation was “urgent”. The mean age of the patients was 71.25 years (range, 52–83 years). In nine cases the bladder cancer was newly diagnosed.

Results

The patients’ preoperative mean hemoglobin concentration was 11.4 g/dl (range = 5.2–13.4 g/dl), and on the first postoperative day it was 10.2 g/dl (range = 9.6–12.6 g/dl). The mean duration of the intervention was 32 min (range = 20–60 min). There were no cardiac complications in either the perioperative or the postoperative period. No patient required reintervention for hemostatic purposes. Three episodes of clot-related acute urinary retention occurred after removal of the bladder catheter, all of which were resolved with replacement of the catheter without needing reintervention.

Conclusion

Despite the high number of complications related to cardiac problems that suspension of these drugs causes, this urological intervention, carried out during dual antithrombotic therapy, was feasible and without major complications. Given the high proportion of complications due to clot-related urinary retention, it is advisable to leave the urinary catheter in place for a longer period.
Literatur
1.
Zurück zum Zitat Steinhubl SR, Berger PB, Mann JT III, Fry ET, DeLago A, Wilmer C, Topol EJ, CREDO Investigators, Clopidogrel for the Reduction of Events During Observation (2002) Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288:2411–2420 Steinhubl SR, Berger PB, Mann JT III, Fry ET, DeLago A, Wilmer C, Topol EJ, CREDO Investigators, Clopidogrel for the Reduction of Events During Observation (2002) Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288:2411–2420
2.
Zurück zum Zitat Gregorini L, Marco J, Fajadet J, Bernies M, Cassagneau B, Brunel P, Bossi IM, Mannucci PM (1997) Ticlopidine and aspirin pretreatment reduces coagulation and platelet activation during coronary dilation procedures. J Am Coll Cardiol 29:13–20PubMedCrossRef Gregorini L, Marco J, Fajadet J, Bernies M, Cassagneau B, Brunel P, Bossi IM, Mannucci PM (1997) Ticlopidine and aspirin pretreatment reduces coagulation and platelet activation during coronary dilation procedures. J Am Coll Cardiol 29:13–20PubMedCrossRef
3.
Zurück zum Zitat Chechi T, Vecchio S, Vittori G, Giuliani G, Lilli A, Spaziani G, Consoli L, Baldereschi G, Biondi-Zoccai GG, Sheiban I, Margheri M (2008) ST-segment elevation myocardial infarction due to early and late stent thrombosis a new group of high-risk patients. J Am Coll Cardiol 51:2396–2402PubMedCrossRef Chechi T, Vecchio S, Vittori G, Giuliani G, Lilli A, Spaziani G, Consoli L, Baldereschi G, Biondi-Zoccai GG, Sheiban I, Margheri M (2008) ST-segment elevation myocardial infarction due to early and late stent thrombosis a new group of high-risk patients. J Am Coll Cardiol 51:2396–2402PubMedCrossRef
4.
Zurück zum Zitat Mayor S (2006) Drug eluting stents are safe for licensed indications, FDA panel says. BMJ 333:1235PubMedCrossRef Mayor S (2006) Drug eluting stents are safe for licensed indications, FDA panel says. BMJ 333:1235PubMedCrossRef
5.
Zurück zum Zitat Silber S, Albertsson P, Avilés FF, Camici PG, Colombo A, Hamm C, Jørgensen E, Marco J, Nordrehaug JE, Ruzyllo W, Urban P, Stone GW, Wijns W (2005) Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 26:804–847PubMedCrossRef Silber S, Albertsson P, Avilés FF, Camici PG, Colombo A, Hamm C, Jørgensen E, Marco J, Nordrehaug JE, Ruzyllo W, Urban P, Stone GW, Wijns W (2005) Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 26:804–847PubMedCrossRef
6.
Zurück zum Zitat Vicenzi MN, Meislitzer T, Heitzinger B, Halaj M, Fleisher LA, Metzler H (2006) Coronary artery stenting and non-cardiac surgery—a prospective outcome study. Br J Anaesth 96:686–693PubMedCrossRef Vicenzi MN, Meislitzer T, Heitzinger B, Halaj M, Fleisher LA, Metzler H (2006) Coronary artery stenting and non-cardiac surgery—a prospective outcome study. Br J Anaesth 96:686–693PubMedCrossRef
7.
Zurück zum Zitat O’Riordan JM, Margey RJ, Blake G, O’Connell PR (2009) Antiplatelet agents in the perioperative period. Arch Surg 144:69–76PubMedCrossRef O’Riordan JM, Margey RJ, Blake G, O’Connell PR (2009) Antiplatelet agents in the perioperative period. Arch Surg 144:69–76PubMedCrossRef
8.
Zurück zum Zitat Luckie MJ, Khattar RS, Fraser DG (2009) Noncardiac surgery and antiplatelet therapy following coronary artery stenting. Heart 95:1303–1308PubMedCrossRef Luckie MJ, Khattar RS, Fraser DG (2009) Noncardiac surgery and antiplatelet therapy following coronary artery stenting. Heart 95:1303–1308PubMedCrossRef
9.
Zurück zum Zitat Grines CL, Bonow RO, Casey DE Jr, Gardner TJ, Lockhart PB, Moliterno DJ, O’Gara P, Whitlow P (2007) Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 115:813–818 Grines CL, Bonow RO, Casey DE Jr, Gardner TJ, Lockhart PB, Moliterno DJ, O’Gara P, Whitlow P (2007) Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 115:813–818
10.
Zurück zum Zitat McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, Suddath WO, Weissman NJ, Torguson R, Kent KM, Pichard AD, Satler LF, Waksman R, Serruys PW (2004) Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 364:1519–1521PubMedCrossRef McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, Suddath WO, Weissman NJ, Torguson R, Kent KM, Pichard AD, Satler LF, Waksman R, Serruys PW (2004) Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 364:1519–1521PubMedCrossRef
11.
Zurück zum Zitat Jeremias A, Sylvia B, Bridges J, Kirtane AJ, Bigelow B, Pinto DS, Ho KK, Cohen DJ, Garcia LA, Cutlip DE, Carrozza JP Jr (2004) Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation 109:1930–1932PubMedCrossRef Jeremias A, Sylvia B, Bridges J, Kirtane AJ, Bigelow B, Pinto DS, Ho KK, Cohen DJ, Garcia LA, Cutlip DE, Carrozza JP Jr (2004) Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation 109:1930–1932PubMedCrossRef
12.
Zurück zum Zitat Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A (2005) Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293:2126–2130PubMedCrossRef Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A (2005) Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293:2126–2130PubMedCrossRef
13.
Zurück zum Zitat Ferrari E, Benhamou M, Cerboni P, Marcel B (2005) Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol 45:456–459PubMedCrossRef Ferrari E, Benhamou M, Cerboni P, Marcel B (2005) Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol 45:456–459PubMedCrossRef
14.
Zurück zum Zitat Ong AT, Hoye A, Aoki J, van Mieghem CA, Rodriguez Granillo GA, Sonnenschein K, Regar E, McFadden EP, Sianos G, van der Giessen WJ, de Jaegere PP, de Feyter P, van Domburg RT, Serruys PW (2005) Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 45:947–953PubMedCrossRef Ong AT, Hoye A, Aoki J, van Mieghem CA, Rodriguez Granillo GA, Sonnenschein K, Regar E, McFadden EP, Sianos G, van der Giessen WJ, de Jaegere PP, de Feyter P, van Domburg RT, Serruys PW (2005) Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 45:947–953PubMedCrossRef
15.
Zurück zum Zitat Urban P, Gershlick AH, Guagliumi G, Guyon P, Lotan C, Schofer J, Seth A, Sousa JE, Wijns W, Berge C, Deme M, Stoll HP (2006) Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation 113:1434–1441PubMedCrossRef Urban P, Gershlick AH, Guagliumi G, Guyon P, Lotan C, Schofer J, Seth A, Sousa JE, Wijns W, Berge C, Deme M, Stoll HP (2006) Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation 113:1434–1441PubMedCrossRef
16.
Zurück zum Zitat Tsimikas S (2006) Drug-eluting stents and late adverse clinical outcomes. J Am Coll Cardiol 47:2112–2115PubMedCrossRef Tsimikas S (2006) Drug-eluting stents and late adverse clinical outcomes. J Am Coll Cardiol 47:2112–2115PubMedCrossRef
17.
Zurück zum Zitat Virmani R, Farb A, Guagliumi G, Kolodgie FD (2004) Drug-eluting stents: caution and concerns for long-term outcome. Coron Artery Dis 15:313–318PubMedCrossRef Virmani R, Farb A, Guagliumi G, Kolodgie FD (2004) Drug-eluting stents: caution and concerns for long-term outcome. Coron Artery Dis 15:313–318PubMedCrossRef
18.
Zurück zum Zitat Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, Mark DB, Kramer JM, Harrington RA, Matchar DB, Kandzari DE, Peterson ED, Schulman KA, Califf RM (2007) Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 297:159–168PubMedCrossRef Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, Mark DB, Kramer JM, Harrington RA, Matchar DB, Kandzari DE, Peterson ED, Schulman KA, Califf RM (2007) Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 297:159–168PubMedCrossRef
19.
Zurück zum Zitat Tanzilli G, Greco C, Pelliccia F, Pasceri V, Barillà F, Paravati V, Pannitteri G, Gaudio C, Mangieri E (2009) Effectiveness of two-year clopidogrel + aspirin in abolishing the risk of very late thrombosis after drug-eluting stent implantation (from the TYCOON [Two-Year ClOpidOgrel Need] study). Am J Cardiol 104:1357–1361PubMedCrossRef Tanzilli G, Greco C, Pelliccia F, Pasceri V, Barillà F, Paravati V, Pannitteri G, Gaudio C, Mangieri E (2009) Effectiveness of two-year clopidogrel + aspirin in abolishing the risk of very late thrombosis after drug-eluting stent implantation (from the TYCOON [Two-Year ClOpidOgrel Need] study). Am J Cardiol 104:1357–1361PubMedCrossRef
20.
Zurück zum Zitat Galløe AM, Thuesen L, Kelbaek H, Thayssen P, Rasmussen K, Hansen PR, Bligaard N, Saunamäki K, Junker A, Aarøe J, Abildgaard U, Ravkilde J, Engstrøm T, Jensen JS, Andersen HR, Bøtker HE, Galatius S, Kristensen SD, Madsen JK, Krusell LR, Abildstrøm SZ, Stephansen GB, Lassen JF (2008) Comparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice. JAMA 299:409–416PubMedCrossRef Galløe AM, Thuesen L, Kelbaek H, Thayssen P, Rasmussen K, Hansen PR, Bligaard N, Saunamäki K, Junker A, Aarøe J, Abildgaard U, Ravkilde J, Engstrøm T, Jensen JS, Andersen HR, Bøtker HE, Galatius S, Kristensen SD, Madsen JK, Krusell LR, Abildstrøm SZ, Stephansen GB, Lassen JF (2008) Comparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice. JAMA 299:409–416PubMedCrossRef
21.
Zurück zum Zitat Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA (2001) Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358:527–533PubMedCrossRef Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA (2001) Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358:527–533PubMedCrossRef
22.
Zurück zum Zitat de Korte FI, van Werkum JW, Vijverberg PL, Ten Berg JM (2008) Late coronary stent thrombosis complicating urologic surgery. Eur Urol 54:221–225PubMedCrossRef de Korte FI, van Werkum JW, Vijverberg PL, Ten Berg JM (2008) Late coronary stent thrombosis complicating urologic surgery. Eur Urol 54:221–225PubMedCrossRef
23.
Zurück zum Zitat Carmignani L, Picozzi S (2009) Re: non-cardiac surgery and antiplatelet therapy following coronary artery stenting. Heart 95:1537PubMedCrossRef Carmignani L, Picozzi S (2009) Re: non-cardiac surgery and antiplatelet therapy following coronary artery stenting. Heart 95:1537PubMedCrossRef
24.
Zurück zum Zitat Sylvester R, Oosterlinck W, van der Meijden A (2004) A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 71:2186–2190CrossRef Sylvester R, Oosterlinck W, van der Meijden A (2004) A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 71:2186–2190CrossRef
25.
Zurück zum Zitat Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes A, Bouffioux C, Denis L, Newling D, Kurth K (2006) Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49:466–477PubMedCrossRef Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes A, Bouffioux C, Denis L, Newling D, Kurth K (2006) Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49:466–477PubMedCrossRef
Metadaten
Titel
Endoscopic resection of bladder cancer in patients receiving double platelet antiaggregant therapy
verfasst von
Luca Carmignani
Stefano Picozzi
Robert Stubinski
Stefano Casellato
Giorgio Bozzini
Luca Lunelli
Domenico Arena
Publikationsdatum
01.07.2011
Verlag
Springer-Verlag
Erschienen in
Surgical Endoscopy / Ausgabe 7/2011
Print ISSN: 0930-2794
Elektronische ISSN: 1432-2218
DOI
https://doi.org/10.1007/s00464-010-1549-1

Weitere Artikel der Ausgabe 7/2011

Surgical Endoscopy 7/2011 Zur Ausgabe

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.